Updated:
Nuwellis, Inc.
Nuwellis, Inc. is a medical technology company, not an investment firm or family office. Its core business revolves around the Aquadex FlexFlow System, an...
Nuwellis, Inc.
Nuwellis, Inc. is a medical technology company, not an investment firm or family office. Its core business revolves around the Aquadex FlexFlow System, an ultrafiltration device approved by the FDA for fluid removal in patients with fluid overload who are unresponsive to diuretics. This therapy is used predominantly in cardiology and critical care settings. The company has historically targeted both hospitals and outpatient clinics as customers. The firm's strategy focuses on commercial expansion of its ultrafiltration platform, including regulatory approvals and clinical evidence generation. Nuwellis has published clinical studies and engaged with health systems to drive adoption. As a publicly traded entity (NASDAQ: NUWE), it does not deploy capital in the manner of an allocator, nor does it manage external assets. Nuwellis maintains a small corporate team, with headquarters listed in the United States. It has not disclosed any affiliated philanthropic foundations or operating companies separate from the public corporation. Recent activity includes regulatory updates and financial filings with the SEC, but no verified operational events specific to this query fall within the most recent 24-month window. The structural differentiator for Nuwellis is its status as a public company in the medical device space, not an investment vehicle. Its governance follows board oversight with shareholder reporting requirements, which is a distinct architecture from family offices or asset managers. The firm's profile here is an artifact of inclusion in a dataset focused on capital allocators.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
null
City
null
Corporate office
null
Sector focus
Frequently asked questions
Why is Nuwellis, Inc. listed in a family office database?
Nuwellis, Inc. is a publicly traded medical technology company, not a family office or investment firm. Its inclusion is the result of an unclassified record in the database, and no investment or family office operations have been identified. Allocators should treat this as a data entry with no capital deployment profile (per public record).
Does Nuwellis, Inc. manage third-party capital or invest in other companies?
No publicly available evidence suggests Nuwellis manages third-party capital or makes investments in external firms. Its business model centers on developing and selling ultrafiltration medical devices for clinical use. The company reports results as a public corporation, not as an investment vehicle (per SEC filings).
What is the AUM or deployment size of Nuwellis, Inc.?
Nuwellis, Inc. does not disclose assets under management or deployment figures as it is not an investment firm. Its financial metrics are revenue, operating expenses, and market capitalization, none of which fit AUM conventions. The firm's AUM is thus reported as Undisclosed (public record).
Who runs investment decisions at Nuwellis, Inc.?
Nuwellis, Inc. does not engage in capital deployment activities typical of family offices or asset managers. Executive management oversees corporate strategy, but no named principals have been identified in an investment context. The firm's officers focus on medical device commercialization, not investment allocation (per public filings).
What investment stages or sectors does Nuwellis, Inc. target?
Nuwellis, Inc. does not target investment stages or sectors as a capital allocator. Its operations are confined to the medical device industry specifically in fluid management therapies. The firm's focus is clinical adoption and regulatory advancement, not portfolio construction (per public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: